Literature DB >> 25930686

Recurrent Clostridium difficile infection: From colonization to cure.

Kelsey Shields1, Roger V Araujo-Castillo2, Thimmaiah G Theethira3, Carolyn D Alonso4, Ciaran P Kelly5.   

Abstract

Clostridium difficile infection (CDI) is increasingly prevalent, dangerous and challenging to prevent and manage. Despite intense national and international attention the incidence of primary and of recurrent CDI (PCDI and RCDI, respectively) have risen rapidly throughout the past decade. Of major concern is the increase in cases of RCDI resulting in substantial morbidity, morality and economic burden. RCDI management remains challenging as there is no uniformly effective therapy, no firm consensus on optimal treatment, and reliable data regarding RCDI-specific treatment options is scant. Novel therapeutic strategies are critically needed to rapidly, accurately, and effectively identify and treat patients with, or at-risk for, RCDI. In this review we consider the factors implicated in the epidemiology, pathogenesis and clinical presentation of RCDI, evaluate current management options for RCDI and explore novel and emerging therapies.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Antibiotic; Fecal microbiota therapy; Infection control; Infectious diarrhea; Nosocomial infection; Toxin

Mesh:

Year:  2015        PMID: 25930686      PMCID: PMC4492812          DOI: 10.1016/j.anaerobe.2015.04.012

Source DB:  PubMed          Journal:  Anaerobe        ISSN: 1075-9964            Impact factor:   3.331


  204 in total

1.  Activity of OPT-80, a novel macrocycle, compared with those of eight other agents against selected anaerobic species.

Authors:  Kim L Credito; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2004-11       Impact factor: 5.191

2.  Prospective derivation and validation of a clinical prediction rule for recurrent Clostridium difficile infection.

Authors:  Mary Y Hu; Kianoosh Katchar; Lorraine Kyne; Seema Maroo; Sanjeev Tummala; Valley Dreisbach; Hua Xu; Daniel A Leffler; Ciarán P Kelly
Journal:  Gastroenterology       Date:  2008-12-13       Impact factor: 22.682

3.  Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec.

Authors:  Jacques Pépin; Nathalie Saheb; Marie-Andrée Coulombe; Marie-Eve Alary; Marie-Pier Corriveau; Simon Authier; Michel Leblanc; Geneviève Rivard; Mathieu Bettez; Valérie Primeau; Martin Nguyen; Claude-Emilie Jacob; Luc Lanthier
Journal:  Clin Infect Dis       Date:  2005-09-20       Impact factor: 9.079

4.  Risk factors for early recurrent Clostridium difficile-associated diarrhea.

Authors:  A N Do; S K Fridkin; A Yechouron; S N Banerjee; G E Killgore; A M Bourgault; M Jolivet; W R Jarvis
Journal:  Clin Infect Dis       Date:  1998-04       Impact factor: 9.079

5.  IL-8 release and neutrophil activation by Clostridium difficile toxin-exposed human monocytes.

Authors:  J K Linevsky; C Pothoulakis; S Keates; M Warny; A C Keates; J T Lamont; C P Kelly
Journal:  Am J Physiol       Date:  1997-12

Review 6.  Clostridium difficile toxins: more than mere inhibitors of Rho proteins.

Authors:  Harald Genth; Stefanie C Dreger; Johannes Huelsenbeck; Ingo Just
Journal:  Int J Biochem Cell Biol       Date:  2008-01-05       Impact factor: 5.085

7.  Fidaxomicin inhibits toxin production in Clostridium difficile.

Authors:  Farah Babakhani; Laurent Bouillaut; Pamela Sears; Carlee Sims; Abraham Gomez; Abraham L Sonenshein
Journal:  J Antimicrob Chemother       Date:  2012-12-02       Impact factor: 5.790

8.  Cadazolid, a novel antibiotic with potent activity against Clostridium difficile: safety, tolerability and pharmacokinetics in healthy subjects following single and multiple oral doses.

Authors:  Daniela Baldoni; Marcelo Gutierrez; Wolfgang Timmer; Jasper Dingemanse
Journal:  J Antimicrob Chemother       Date:  2013-10-08       Impact factor: 5.790

9.  Fidaxomicin inhibits Clostridium difficile toxin A-mediated enteritis in the mouse ileum.

Authors:  Hon Wai Koon; Samantha Ho; Tressia C Hing; Michelle Cheng; Xinhua Chen; Yoshi Ichikawa; Ciarán P Kelly; Charalabos Pothoulakis
Journal:  Antimicrob Agents Chemother       Date:  2014-06-02       Impact factor: 5.191

10.  Development and validation of a recurrent Clostridium difficile risk-prediction model.

Authors:  Marya D Zilberberg; Kimberly Reske; Margaret Olsen; Yan Yan; Erik R Dubberke
Journal:  J Hosp Med       Date:  2014-04-04       Impact factor: 2.960

View more
  32 in total

Review 1.  Considering the Immune System during Fecal Microbiota Transplantation for Clostridioides difficile Infection.

Authors:  Alyse L Frisbee; William A Petri
Journal:  Trends Mol Med       Date:  2020-02-17       Impact factor: 11.951

2.  Clostridium difficile Infection and the Role of Adaptive Immunity in the Microbiome.

Authors:  Monika Fischer
Journal:  Gastroenterol Hepatol (N Y)       Date:  2017-05

Review 3.  Nutrition and the gut microbiome in the elderly.

Authors:  Nuria Salazar; Lorena Valdés-Varela; Sonia González; Miguel Gueimonde; Clara G de Los Reyes-Gavilán
Journal:  Gut Microbes       Date:  2016-11-03

4.  Colon Surgery Risk With Corticosteroids Versus Immunomodulators or Biologics in Inflammatory Bowel Disease Patients With Clostridium difficile Infection.

Authors:  Dipesh Solanky; Darrell S Pardi; Edward V Loftus; Sahil Khanna
Journal:  Inflamm Bowel Dis       Date:  2019-02-21       Impact factor: 5.325

Review 5.  Rapid detection of Clostridium difficile toxins and laboratory diagnosis of Clostridium difficile infections.

Authors:  Shuyi Chen; Huawei Gu; Chunli Sun; Haiying Wang; Jufang Wang
Journal:  Infection       Date:  2016-09-06       Impact factor: 3.553

6.  A Clostridium difficile alanine racemase affects spore germination and accommodates serine as a substrate.

Authors:  Ritu Shrestha; Steve W Lockless; Joseph A Sorg
Journal:  J Biol Chem       Date:  2017-05-09       Impact factor: 5.157

Review 7.  Acid-Suppressive Therapy and Risk of Infections: Pros and Cons.

Authors:  Leon Fisher; Alexander Fisher
Journal:  Clin Drug Investig       Date:  2017-07       Impact factor: 2.859

Review 8.  Bezlotoxumab: A Review in Preventing Clostridium difficile Infection Recurrence.

Authors:  Emma D Deeks
Journal:  Drugs       Date:  2017-10       Impact factor: 9.546

9.  Disease Progression and Resolution in Rodent Models of Clostridium difficile Infection and Impact of Antitoxin Antibodies and Vancomycin.

Authors:  Peter Warn; Pia Thommes; Abdul Sattar; David Corbett; Amy Flattery; Zuo Zhang; Todd Black; Lorraine D Hernandez; Alex G Therien
Journal:  Antimicrob Agents Chemother       Date:  2016-10-21       Impact factor: 5.191

10.  Administration of probiotic kefir to mice with Clostridium difficile infection exacerbates disease.

Authors:  Jennifer K Spinler; Aaron Brown; Caná L Ross; Prapaporn Boonma; Margaret E Conner; Tor C Savidge
Journal:  Anaerobe       Date:  2016-05-11       Impact factor: 3.331

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.